Glucose Lowering in Non-diabetic hyperglycaemia Trial

OVERVIEW

The Glucose Lowering In Non-diabetic hyperglycaemia Trial (GLINT) was a multi-centre, randomised, double-blind, parallel-group, pragmatic,  primary prevention trial comparing the effect of slow-release metformin with placebo on a macrovascular composite outcome in people in primary care with non-diabetic hyperglycaemia and at high cardiovascular risk. Participants were allocated randomly to treatment with either metformin XR or placebo, and were followed for 5-7 years.

GLINT was run jointly by the University of Cambridge MRC Epidemiology Unit, the University of Oxford Diabetes Trials Unit (DTU) and the Leicester Diabetes Centre.  The joint trial Sponsors were the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The feasibility phase of GLINT was funded by the NIHR Health Technology Assessment (HTA) programme.

The GLINT feasibility phase of 500 individuals ran from 2015-2017 with a plan to expand in the main trial to approximately 12,900 UK participants.

The results are available here.